MINJUVI/MONJUVI — Total revenues
Incyte MINJUVI/MONJUVI — Total revenues increased by 17.5% to $49.23M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 66.6%, from $29.55M to $49.23M. Over 3 years (FY 2022 to FY 2025), MINJUVI/MONJUVI — Total revenues shows an upward trend with a 94.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded patient access for the therapy, while a decrease may signal increased competition, loss of market share, or changes in clinical guidelines.
Detailed definition
This metric represents the total gross revenue generated from the sale and commercialization of the Monjuvi/Minjuvi prod...
Peer comparison
Comparable to product-specific revenue lines reported by other biopharmaceutical companies, often benchmarked against oncology franchise growth rates and therapeutic area market share.
incy_segment_minjuvi_monjuvi_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.91M | $4.91M | $4.91M | $4.91M | $6.56M | $13.16M | $8.35M | $8.99M | $23.87M | $31.12M | $31.44M | $32.81M | $29.55M | $31.13M | $41.99M | $41.91M | $49.23M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +33.4% | +100.7% | -36.6% | +7.7% | +165.4% | +30.3% | +1.0% | +4.4% | -9.9% | +5.3% | +34.9% | -0.2% | +17.5% |
| YoY Change | — | — | — | — | +33.4% | +167.8% | +69.9% | +83.0% | +264.2% | +136.5% | +276.6% | +264.8% | +23.8% | +0.0% | +33.6% | +27.7% | +66.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's minjuvi/monjuvi — total revenues?
- Incyte (INCY) reported minjuvi/monjuvi — total revenues of $49.23M in Q1 2026.
- How has Incyte's minjuvi/monjuvi — total revenues changed year-over-year?
- Incyte's minjuvi/monjuvi — total revenues increased by 66.6% year-over-year, from $29.55M to $49.23M.
- What is the long-term trend for Incyte's minjuvi/monjuvi — total revenues?
- Over 3 years (2022 to 2025), Incyte's minjuvi/monjuvi — total revenues has grown at a 94.5% compound annual growth rate (CAGR), from $19.65M to $144.58M.
- What does minjuvi/monjuvi — total revenues mean?
- The total sales revenue generated by the Monjuvi/Minjuvi oncology product line.